Fungal Infection


SCYNEXIS Reports Data from Second Interim Analysis of Ongoing Phase 3 FURI Study, Oral Ibrexafungerp Effective in Treating Severe Fungal Infections in Hospital Setting

SCYNEXIS announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal...

Pin It on Pinterest